Ulcere delle gambe e melanonichia in bande longitudinali e trasversali in corso di terapia con idrossiurea

Translated title of the contribution: Leg ulcers, longitudinal and transverse melanonychia following hydroxyurea therapy

A. Bonci, V. Di Lernia, G. Bisighini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The authors report a 79 year-old-woman with essential thrombocytosis treated with hydroxyurea (1.000-1.500 mg/day) since 3 years, who developed after 2 years multiple painful ulcers on both lower legs. In addition nail, and toenail melanonychia striata was noted. The ulcers were located on the malleoli, ankles, and heels. More recently, transverse melanonychia in a few nails was observed. There was no diabetes mellitus or underlying vascular disease. The treatment consisted in local dressing and rest with slow improvement of the ulcers. Hydroxyurea is a cytostatic agent used mainly in patients with myeloproliferative disorders. Several cutaneous side effects have been described during long-term hydroxyurea treatment, such as xerosis and atrophy, ulcers, diffuse hyperpigmentation, chromonychia, dermatomyositis-like-eruptions, basal and squamous cell carcinomas. Cutaneous side-effects induced by hydroxyurea are underestimated because they are usually benign. If hydroxyurea is required for internal disease, as well as in our case, therapy could be continued. However, refractory painful leg ulcers and squamous cell carcinomas are the conditions which need to change the treatment. Melanonychia striata is the usual pattern of nail hyperpigmentation although diffuse and transverse hyperpigmentation can be rarely observed.

Original languageItalian
Pages (from-to)231-235
Number of pages5
JournalGiornale Italiano di Dermatologia e Venereologia
Volume136
Issue number3
Publication statusPublished - 2001

Fingerprint

Leg Ulcer
Hydroxyurea
Nails
Hyperpigmentation
Ulcer
Squamous Cell Carcinoma
Therapeutics
Thrombocytosis
Myeloproliferative Disorders
Skin
Dermatomyositis
Heel
Basal Cell Carcinoma
Cytostatic Agents
Bandages
Vascular Diseases
Ankle
Atrophy
Leg
Diabetes Mellitus

ASJC Scopus subject areas

  • Dermatology

Cite this

Ulcere delle gambe e melanonichia in bande longitudinali e trasversali in corso di terapia con idrossiurea. / Bonci, A.; Di Lernia, V.; Bisighini, G.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 136, No. 3, 2001, p. 231-235.

Research output: Contribution to journalArticle

@article{e18a93a173d046e6b4fdb03ebd6f02ce,
title = "Ulcere delle gambe e melanonichia in bande longitudinali e trasversali in corso di terapia con idrossiurea",
abstract = "The authors report a 79 year-old-woman with essential thrombocytosis treated with hydroxyurea (1.000-1.500 mg/day) since 3 years, who developed after 2 years multiple painful ulcers on both lower legs. In addition nail, and toenail melanonychia striata was noted. The ulcers were located on the malleoli, ankles, and heels. More recently, transverse melanonychia in a few nails was observed. There was no diabetes mellitus or underlying vascular disease. The treatment consisted in local dressing and rest with slow improvement of the ulcers. Hydroxyurea is a cytostatic agent used mainly in patients with myeloproliferative disorders. Several cutaneous side effects have been described during long-term hydroxyurea treatment, such as xerosis and atrophy, ulcers, diffuse hyperpigmentation, chromonychia, dermatomyositis-like-eruptions, basal and squamous cell carcinomas. Cutaneous side-effects induced by hydroxyurea are underestimated because they are usually benign. If hydroxyurea is required for internal disease, as well as in our case, therapy could be continued. However, refractory painful leg ulcers and squamous cell carcinomas are the conditions which need to change the treatment. Melanonychia striata is the usual pattern of nail hyperpigmentation although diffuse and transverse hyperpigmentation can be rarely observed.",
keywords = "Adverse effects - Melanosis, Chemically induced - Nail diseases, Chemically induced - Thrombocytosis, Drug therapy, Etiology - Hydroxyurea, Leg ulcer - Pigmentation disorders",
author = "A. Bonci and {Di Lernia}, V. and G. Bisighini",
year = "2001",
language = "Italian",
volume = "136",
pages = "231--235",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Ulcere delle gambe e melanonichia in bande longitudinali e trasversali in corso di terapia con idrossiurea

AU - Bonci, A.

AU - Di Lernia, V.

AU - Bisighini, G.

PY - 2001

Y1 - 2001

N2 - The authors report a 79 year-old-woman with essential thrombocytosis treated with hydroxyurea (1.000-1.500 mg/day) since 3 years, who developed after 2 years multiple painful ulcers on both lower legs. In addition nail, and toenail melanonychia striata was noted. The ulcers were located on the malleoli, ankles, and heels. More recently, transverse melanonychia in a few nails was observed. There was no diabetes mellitus or underlying vascular disease. The treatment consisted in local dressing and rest with slow improvement of the ulcers. Hydroxyurea is a cytostatic agent used mainly in patients with myeloproliferative disorders. Several cutaneous side effects have been described during long-term hydroxyurea treatment, such as xerosis and atrophy, ulcers, diffuse hyperpigmentation, chromonychia, dermatomyositis-like-eruptions, basal and squamous cell carcinomas. Cutaneous side-effects induced by hydroxyurea are underestimated because they are usually benign. If hydroxyurea is required for internal disease, as well as in our case, therapy could be continued. However, refractory painful leg ulcers and squamous cell carcinomas are the conditions which need to change the treatment. Melanonychia striata is the usual pattern of nail hyperpigmentation although diffuse and transverse hyperpigmentation can be rarely observed.

AB - The authors report a 79 year-old-woman with essential thrombocytosis treated with hydroxyurea (1.000-1.500 mg/day) since 3 years, who developed after 2 years multiple painful ulcers on both lower legs. In addition nail, and toenail melanonychia striata was noted. The ulcers were located on the malleoli, ankles, and heels. More recently, transverse melanonychia in a few nails was observed. There was no diabetes mellitus or underlying vascular disease. The treatment consisted in local dressing and rest with slow improvement of the ulcers. Hydroxyurea is a cytostatic agent used mainly in patients with myeloproliferative disorders. Several cutaneous side effects have been described during long-term hydroxyurea treatment, such as xerosis and atrophy, ulcers, diffuse hyperpigmentation, chromonychia, dermatomyositis-like-eruptions, basal and squamous cell carcinomas. Cutaneous side-effects induced by hydroxyurea are underestimated because they are usually benign. If hydroxyurea is required for internal disease, as well as in our case, therapy could be continued. However, refractory painful leg ulcers and squamous cell carcinomas are the conditions which need to change the treatment. Melanonychia striata is the usual pattern of nail hyperpigmentation although diffuse and transverse hyperpigmentation can be rarely observed.

KW - Adverse effects - Melanosis

KW - Chemically induced - Nail diseases

KW - Chemically induced - Thrombocytosis

KW - Drug therapy

KW - Etiology - Hydroxyurea

KW - Leg ulcer - Pigmentation disorders

UR - http://www.scopus.com/inward/record.url?scp=0034946515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034946515&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0034946515

VL - 136

SP - 231

EP - 235

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 3

ER -